The Impact of miRNA-425 and miRNA-373 in the Pathogenesis of Breast Cancer miRNA-425 and miRNA-373 in BC
Abstract
Background: Biomarkers that monitor treatment efficacy could be very useful for early response evaluation, therapy direction, and prognosis prediction. MicroRNAs (miRNAs), a type of noncoding RNA that is only 22 nucleotides long regulate genes after transcription has taken place. miRNAs are essential regulators of cancer biology and are involved in the regulation of key processes such as cell proliferation, apoptosis, migration, and metastasis.
Methods: This study included 100 women with breast cancer (BC) who attended Al-Amal Hospital in Baghdad, Iraq between June 2023 and October 2023. The parameters were evaluated using questionnaires and medical records, including human epidermal growth factor receptor 2 (HER2) receptors, disease progesterone (PR), grade, age, tumor stage, family history, type, location, and estrogen (ER).
Results: The serum Sera' levels (median (IQR)) were significantly higher in patients with BC than in healthy controls (HCs), 104.05 pg/ml versus 26.85 pg/ml (P< 0.001). Sera' levels (median (IQR)) of RETN were significantly higher in the BC group in comparison with HCs, 1.16 ng/ml versus 0.41 ng/ml, respectively (P< 0.001). The expression levels of miR-373 were significantly higher in the BC group than in the HCs (median (IQR)), 3.54 (8.23) fold change versus 1 fold change, respectively (P< 0.001). The expression levels of miR-425 were significantly higher in the BC group than in the HCs (median (IQR)), 4.80 (10.22) versus 1 fold change, respectively (P< 0.001).
Conclusion: The biomarkers CEA, RETN, miR-373, and miR-425 were identified as promising candidates for enhancing the diagnostic workup, prognosis, and therapy of BC. CEA and RETN are established markers that aid in the early detection and monitoring of tumor progression, whereas miR-373 and miR-425 are involved in critical processes such as tumor metastasis, EMT, and chemo resistance.
Full text article
References
Abdallah M, Aziz IH, Alsammarraie AZ. (2024) “Assessment of miRNA‐10b Expression Levels as a Potential Precursor to Metastasis in Localized and Locally Advanced/Metastatic Breast Cancer among Iraqi Patients.” Int J Breast Cancer. 2024;2024(1):2408355.
Hussain AM, Ali AH, Mohammed HL. (2022) “Correlation between serum and tissue markers in breast cancer Iraqi patients.” Baghdad Sci J. 2022;19(3):501.
Sahan KA, Aziz IH, Dawood SN, Al Qazzaz H. (2022) “The role of resistin gene polymorphism in Iraqi breast cancer patients.” Biomedicine. 2022;42(6):1296-1300.
Siegel RL, Miller KD, Fuchs HE, Jemal A. (2022) “Cancer statistics, 2022.” CA Cancer J Clin. 2022;72(1):7-33. doi:10.3322/caac.21708
Abbas R, Aziz I. (2022) “A study comparing the oncogenic microRNA-21-5p and the CA15-3 characteristics as an effective tumor marker in breast cancer patients from Iraq.” Bionatura. 2022;7:1-7. doi:10.21931/RB/2022.07.04.10
Bodaghi A, Fattahi N, Ramazani A. (2023) “Biomarkers: Promising and valuable tools towards diagnosis, prognosis and treatment of Covid-19 and other diseases.” Heliyon. 2023;9(2).
Abed RM, Yaaqoob LA. (2023) “Novel single nucleotide polymorphism (rs1600485907) of IL-41 gene associated with systemic lupus erythematous.” Asia-Pacific J Mol Biol Biotechnol. 2023;31(4):1-8.
AL-saqabi ANI, Aziz IH. (2023) “The expression miRNA-195 in a sample of Iraqi breast cancer pa-tients.” Bionatura. 2023;8(3):1-6.
Salih AM, Aziz IH, Mohsin FY. (2023) “Role of miRNA 199a-5p Expression in Iraqi Women with Breast Cancer.” Al-Rafidain J Med Sci (ISSN 2789-3219). 2023;5(1S):S94-99.
Zhang Y, Zhao J, Wang Y, et al. (2022) “Changes of tumor markers in patients with breast cancer during postoperative adjuvant chemotherapy.” Dis Markers. 2022;2022(1):7739777.
Anoop TM, Soman S, Chacko S, Mathew M. (2022) “Significance of serum carcinoembryonic antigen in metastatic breast cancer patients: A prospective study.” World J Clin Oncol. 2022;13(6):529.
Sahan KA, Aziz IH, Dawood SN, Razzaq SSA. (2023) “Evaluation of miR-146 and miR-196 as potential biomarkers in a sample of Iraqi breast cancer patients.” Bionatura. 2023;8(2):1-2.
Shin JH, Park S, Cho H, Kim JH, Choi H. (2022) “Adipokine human Resistin promotes obesity-associated inflammatory intervertebral disc degeneration via pro-inflammatory cytokine cascade activation.” Sci Rep. 2022;12(1):8936.
Wang CH, Wang PJ, Hsieh YC, et al. (2018) “Resistin facilitates breast cancer progression via TLR4-mediated induction of mesenchymal phenotypes and stemness properties.” Oncogene. 2018;37(5):589-600.
Lee JO, Kim N, Lee HJ, et al. (2016) “Resistin, a fat-derived secretory factor, promotes metastasis of MDA-MB-231 human breast cancer cells through ERM activation.” Sci Rep. 2016;6(1):18923.
Mohsin RN, Mohamad BJ. (2024) “Clinical and Histopathological Features of Breast Cancer in Iraqi Patients between 2018-2021.” Iraqi J Sci. Published online 2024:90-107.
Yang Y, Zhang H, Zhang M, Meng Q, Cai L, Zhang Q. (2017) “Elevation of serum CEA and CA15‑3 levels during antitumor therapy predicts poor therapeutic response in advanced breast cancer patients.” Oncol Lett. 2017;14(6):7549-7556.
Khushk M, Khan A, Rehman A, et al. (2021) “The role of tumor markers: carcinoembryonic antigen and cancer antigen 15-3 in patients with breast cancer.” Cureus. 2021;13(7).
Puglisi F, Fontanella C, Numico G, et al. (2014) “Follow-up of patients with early breast cancer: is it time to rewrite the story?” Crit Rev Oncol Hematol. 2014;91(2):130-141.
Rasmy A, Abozeed W, Elsamany S, et al. (2016) “Correlation of preoperative Ki67 and serum CA15. 3 levels with outcome in early breast cancers a multi institutional study.” Asian Pacific J Cancer Prev. 2016;17(7):3595-3600.
Bhindi B, Leibovich BC. (2018) “Re: Robotic versus Open Level I-II Inferior Vena Cava Thrombectomy: A Matched Group Comparative Analysis: L. Gu, X. Ma, Y. Gao, H. Li, X. Li, L. Chen, B. Wang, Y. Xie, Y. Fan and X. Zhang: J Urol 2017;: 198:: 1241–1246.” J Urol. 2018;199(5):1351-1352.
Araz M, Beypinar I, Kazan S, Inci F, Celiker M, Uysal M. (2019) “Are preoperative serum CA15-3 levels different in breast cancer subgroups?” Curr Probl Cancer. 2019;43(2):115-122.
Nam S eun, Lim W, Jeong J, et al. (2019) “The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry.” Breast Cancer Res Treat. 2019;177:669-678.
Li J, Liu L, Feng Z, et al. (2020) “Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study.” Breast Cancer. 2020;27:621-630.
Hou W-K, Xu Y-X, Yu T, et al. (2007) “Adipocytokines and breast cancer risk.” Chin Med J (Engl). 2007;120(18):1592-1596.
Dalamaga M, Sotiropoulos G, Karmaniolas K, Pelekanos N, Papadavid E, Lekka A. (2013) “Serum resistin: a biomarker of breast cancer in postmenopausal women? Association with clinicopathological characteristics, tumor markers, inflammatory and metabolic parameters.” Clin Biochem. 2013;46(7-8):584-590.
Assiri AMA, Kamel HFM, Hassanien MFR. (2015) “Resistin, visfatin, adiponectin, and leptin: risk of breast cancer in pre‐and postmenopausal saudi females and their possible diagnostic and predictive implications as novel biomarkers.” Dis Markers. 2015;2015(1):253519.
Georgiou GP, Provatopoulou X, Kalogera E, et al. (2016) “Serum resistin is inversely related to breast cancer risk in premenopausal women.” The Breast. 2016;29:163-169.
Deb A, Deshmukh B, Ramteke P, Bhati FK, Bhat MK. (2021) “Resistin: A journey from metabolism to cancer.” Transl Oncol. 2021;14(10):101178.
Hlavna M, Kohút L, Lipková J, et al. (2011) “Relationship of resistin levels with endometrial cancer risk.” Neoplasma. 2011;58(2):124-128.
Liu W, Li M, Chen X, et al. (2015) “MicroRNA-373 promotes migration and invasion in human esophageal squamous cell carcinoma by inhibiting TIMP3 expression.” Am J Cancer Res. 2015;6(1):1.
Tu H, Chang K, Cheng H, Liu C. (2015) “Upregulation of mi R‐372 and‐373 associates with lymph node metastasis and poor prognosis of oral carcinomas.” Laryngoscope. 2015;125(11):E365-E370.
Wei F, Cao C, Xu X, Wang J. (2015) “Diverse functions of miR-373 in cancer.” J Transl Med. 2015;13:1-8.
Bakr NM, Mahmoud MS, Nabil R, Boushnak H, Swellam M. (2021) “Impact of circulating miRNA-373 on breast cancer diagnosis through targeting VEGF and cyclin D1 genes.” J Genet Eng Biotechnol. 2021;19(1):84.
Huang Q, Gumireddy K, Schrier M, et al. (2008) “The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis.” Nat Cell Biol. 2008;10(2):202-210.
Tavazoie SF, Alarcón C, Oskarsson T, et al. (2008) “Endogenous human microRNAs that suppress breast cancer metastasis.” Nature. 2008;451(7175):147-152.
Xiao S, Zhu H, Luo J, Wu Z, Xie M. (2019) “miR‑425‑5p is associated with poor prognosis in patients with breast cancer and promotes cancer cell progression by targeting PTEN.” Oncol Rep. 2019;42(6):2550-2560.
Zhang L, Zhang J, Zhou H, et al. (2020) “MicroRNA‐425‐5p promotes breast cancer cell growth by inducing PI3K/AKT signaling.” Kaohsiung J Med Sci. 2020;36(4):250-256.
Raheem AR, Abdul-Rasheed OF, Khattab OS, Alsammarraie AZ, Al-Aubaidy H, Abid HA. (2024) “Circulating miRNA-373 and Vascular Endothelial Growth Factor as Potential Biomarkers for Early Detection of Breast Cancer.” Indian J Clin Biochem. Published online 2024:1-10.
Authors
Copyright (c) 2025 Archives of Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.